Form 4: Aptevo Therapeutics Inc. Executive Daphne Taylor Reports Stock Transactions
SEC Form 4 Filing
Daphne Taylor, SVP and CFO of Aptevo Therapeutics Inc., reports the vesting and conversion of Restricted Stock Units (RSUs) into common stock.
Summary
- On August 8, 2024, Daphne Taylor, SVP and CFO of Aptevo Therapeutics Inc., reported transactions involving Restricted Stock Units (RSUs).
- Taylor converted 158 RSUs into common stock.
- These RSUs are part of a grant from August 9, 2022, which vested in two approximately equal annual installments starting August 8, 2023.
- The RSUs convert into common stock on a one-for-one basis.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 08/09/2022 | Reporting person was granted 13,889 (315 post-split) RSUs. |
| 08/08/2023 | First vesting date of RSUs in two approximately equal annual installments. |
| 08/08/2024 | Transaction date: conversion of 158 RSUs into common stock. |
| 08/09/2024 | Date of report filing. |
Keywords
Aptevo Therapeutics, Daphne Taylor, RSU, Restricted Stock Units, Form 4, Stock Transaction, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.